XTL Biopharmaceuticals Ltd. (XTLB)

NCM – Real Time Price. Currency in USD

2.61

-0.24 (-8.42%)

At close: May 12, 2026, 4:00 PM EDT

29.04.2026

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum

20.03.2026

XTL Biopharmaceuticals Announces ADS Ratio Change

RAMAT GAN, ISRAEL, March 20, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it plans to change the ratio of its American Depositary Shares ("ADSs") to its ordinary shares, par value NIS0.1 per share (the "ADS Ratio"), from the current ADS Ratio of one (1) ADS to one hundred (100) ordinary shares, to a new ADS Ratio of one (1) ADS to four hundred (400) ordinary shares (the "ADS Ratio Change"). The Company anticipates that the ADS Ratio Change will be effective on March 25, 2026 (the "Effective Date").

27.02.2026

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

RAMAT GAN, ISRAEL, Feb. 27, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a letter (the “Letter”) from The Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), dated February 25, 2026, notifying the Company of the Staff's belief, based upon its review of the Company and pursuant to Nasdaq Listing Rule 5101, that the Company is a “public shell”, and that continued listing of the Company's American Depositary Shares (“ADSs”) is no longer warranted. The Company intends to request a hearing (the “Hearing”) to appeal the delisting process before a Nasdaq Hearings Panel (the “Panel”). A Hearing request will stay the suspension of the ADSs and delisting pending the Panel's decision.

29.01.2026

XTL Update on Recent Developments

RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company's Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million.

23.01.2026

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RAMAT GAN, ISRAEL, Jan. 23, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated January 20, 2026, notifying the Company that the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(b)(1), to maintain a minimum of $2,500,000 in stockholders' equity for continued listing. This Nasdaq determination was based on (i) the Company's Form 6-K, dated December 30, 2025, that included financial information for the period ended June 30, 2025, and which reported stockholders' equity deficit of $47,000, and (ii) that the Company does not meet the alternatives of market value of listed securities or net income from continuing operations as of January 20, 2026.

13.01.2026

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majority owner of NeuroNOS, to hold 19.99% of XTL's post-transaction share capital Beyond Air to receive up to $32.5 million in upfront, development and commercial milestone payments TEL AVIV and BOSTON, Jan. 13, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd.

24.12.2025

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

RAMAT GAN, ISRAEL, Dec. 24, 2025 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced today that it has received a notification letter from The Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated December 22, 2025, notifying the Company that based on XTL's closing bid price for the last 30 consecutive business days, the Company currently does not meet the continued listing requirement of Nasdaq, under Nasdaq Listing Rules 5550(a)(2), to maintain a minimum bid price of $1 per share.

Videos

No Data

There is no data to display

Press releases

29.04.2026

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

Transaction Positions XTL at the Forefront of the Rapidly Expanding Global Psychedelic Therapeutics Market Following Major U.S. Regulatory Momentum

20.03.2026

XTL Biopharmaceuticals Announces ADS Ratio Change

27.02.2026

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

29.01.2026

XTL Biopharmaceuticals Ltd. (XTLB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Videos

No Data

Press releases

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Videos

No Data

Press releases

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

Search stocks

XTL Biopharmaceuticals Ltd. (XTLB)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Videos

No Data

Press releases

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments

XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership

XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

Videos

No Data

Press releases

XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies

XTL Biopharmaceuticals Announces ADS Ratio Change

XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing

XTL Update on Recent Developments